


Attorney Docket No.: T1566P  
 Application No.: 10/505,538  
 Filing Date: August 19, 2004  
 Page No.: 3

### Amendment to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (previously presented) A compound of formula (I):



wherein

A, B, D and E are each C or N with the proviso that one or more are N;

R<sup>1</sup> and R<sup>2</sup> are each independently hydrogen, halogen, hydroxy, C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, haloC<sub>1-6</sub>alkyl, hydroxyC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, haloC<sub>1-6</sub>alkoxy, hydroxyC<sub>1-6</sub>alkoxy, C<sub>3-7</sub>cycloalkyl, C<sub>3-5</sub>cycloalkylC<sub>1-4</sub>alkyl, NR<sup>7</sup>R<sup>8</sup>, carboxy, esterified carboxy, C<sub>1-6</sub>alkyl substituted with a group selected from NR<sup>7</sup>R<sup>8</sup>, carboxy and esterified carboxy, or C<sub>1-6</sub>alkoxy substituted with a group selected from NR<sup>7</sup>R<sup>8</sup>, carboxy and esterified carboxy;

R<sup>3</sup> and R<sup>4</sup> are each independently hydrogen, C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl or C<sub>2-6</sub>alkynyl;

R<sup>5</sup> and R<sup>6</sup> are, at each occurrence, independently hydrogen, C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>acyloxy, carboxy, esterified carboxy, CONR<sup>7</sup>R<sup>8</sup>, SO<sub>2</sub>R<sup>7</sup>, SO<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>, aryl, heteroaryl, heterocyclyl, or C<sub>1-6</sub>alkyl substituted with a group selected from hydroxy, C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>acyloxy, carboxy, esterified carboxy, NR<sup>7</sup>R<sup>8</sup>, CONR<sup>7</sup>R<sup>8</sup>, SR<sup>7</sup>, SO<sub>2</sub>R<sup>7</sup>, SO<sub>2</sub>NR<sup>7</sup>R<sup>8</sup>, aryl, heteroaryl and heterocyclyl;

or R<sup>5</sup> and R<sup>6</sup> and the carbon atom to which they are attached together form a carbocyclic ring of 3 to 6 carbon atoms;

R<sup>7</sup> and R<sup>8</sup> are, at each occurrence, independently hydrogen, C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, C<sub>3-7</sub>cycloalkyl or fluoroC<sub>1-6</sub>alkyl;

or R<sup>7</sup> and R<sup>8</sup> and the nitrogen atom to which they are attached together form a heteroaliphatic ring of 4 to 7 ring atoms, optionally substituted by one or two groups selected from hydroxy or C<sub>1-6</sub>alkoxy, which ring may optionally contain as one of the said ring atoms an oxygen or a sulfur atom, a group S(O) or

Attorney Docket No.: T1566P  
Application No.: 10/505,538  
Filing Date: August 19, 2004  
Page No.: 4

S(O)<sub>2</sub>, or a second nitrogen atom which will be part of a NH or NR<sup>a</sup> moiety where R<sup>a</sup> is C<sub>1-4</sub>alkyl optionally substituted by hydroxy or C<sub>1-4</sub>alkoxy;  
X is an oxygen or sulfur atom or the group =NCN;  
Y is an aryl, heteroaryl, carbocyclyl or fused-carbocyclyl group; and  
n is either zero or an integer from 1 to 3;  
or a pharmaceutically acceptable salt, N-oxide or a prodrug thereof.

2. (previously presented) A compound according to claim 1 in which X is O.
3. (currently amended) A compound according to claim 1 or 2 in which R<sup>3</sup> and R<sup>4</sup> are hydrogen.
4. (currently amended) A compound according to claim 1, 2 or 3 in which B is nitrogen and A, D and E are carbon.
5. (currently amended) A compound according to ~~any preceding claim in which~~ claim 1 wherein Y is an aryl group selected from unsubstituted phenyl or naphthyl and phenyl or naphthyl substituted by one or two substituents selected from halogen, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, haloC<sub>1-4</sub>alkyl, haloC<sub>1-4</sub>alkoxy, phenyl, cyano, nitro, pyrazolyl, di(C<sub>1-6</sub>alkyl)amino, phenoxy, -OCH<sub>2</sub>O- and C<sub>1-6</sub>alkylcarbonyl; or a heteroaryl group selected from pyridyl, thiazolyl, isoxazolyl, oxadiazolyl and pyrazolyl wherein each heteroaryl group is optionally substituted with one or two substituents selected from C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, haloC<sub>1-4</sub>alkyl, haloC<sub>1-4</sub>alkoxy, unsubstituted heteroaryl or phenyl which may be substituted by C<sub>1-6</sub>alkyl or halogen; or a carbocyclyl group which is a C<sub>5-7</sub>cycloalkyl radical that is unsubstituted or substituted by a phenyl ring; or a fused-carbocyclyl group which is a C<sub>5-7</sub>cycloalkyl radical that is fused to a phenyl ring.
6. (currently amended) A compound according to ~~any preceding claim~~ claim 1 wherein R<sup>5</sup> and R<sup>6</sup> each independently represent a hydrogen atom or a C<sub>1-4</sub>alkyl or phenyl group.
7. (currently amended) A pharmaceutical composition comprising a compound according to ~~any preceding claim~~ claim 1 or a pharmaceutically acceptable salt or N-oxide thereof.

Attorney Docket No.: T1566P  
 Application No.: 10/505,538  
 Filing Date: August 19, 2004  
 Page No.: 5

8. (currently amended) A compound according to ~~any one of claims 1 to 6~~ claim 1 or a pharmaceutically acceptable salt or N-oxide thereof for use in a method of treatment of the human or animal body by therapy.

9. (currently amended) Use of a compound according to ~~any one of claims 1 to 6~~ claim 1 or a pharmaceutically acceptable salt or N-oxide thereof for use in the manufacture of a medicament for treating diseases and conditions in which pain and/or inflammation predominates.

10. (previously presented) A method of treating a subject suffering from a disease or condition in which pain and/or inflammation predominates which comprises administering to that subject a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt or N-oxide thereof.

11. (new) A compound selected from:

*N*-Benzyl-*N*-isoquinolin-5-ylurea, *N*-(1,1'-Biphenyl-4-ylmethyl)-*N*-isoquinolin-5-ylurea, *N*-(1,1'-Biphenyl-3-ylmethyl)-*N*-isoquinolin-5-ylurea, *N*-Isoquinolin-5-yl-*N*-(3-phenylpropyl)urea, *N*-Isoquinolin-5-yl-*N*-(1,2,3,4-tetrahydronaphthalen-2-ylmethyl)urea, *N*-[2-(4-Chlorophenyl)ethyl]-*N*-isoquinolin-5-ylurea, *N*-[3,5-bis(Trifluoromethyl)benzyl]-*N*-isoquinolin-5-ylurea, *N*-[3-(3,4-dimethylphenyl)propyl]-*N*-isoquinolin-5-ylurea, *N*-(4-*tert*-Butylbenzyl)-*N*-isoquinolin-8-ylurea, *N*-(4-*tert*-Butylbenzyl)-*N*-isoquinolin-5-ylurea, *N*-(4-*tert*-Butylbenzyl)-*N*-quinolin-5-ylurea, *N*-(3-*tert*-Butylbenzyl)-*N*-isoquinolin-5-ylurea, *N*-[2-(4-*tert*-Butylphenyl)ethyl]-*N*-isoquinolin-5-ylurea, *N*-Isoquinolin-5-yl-*N*-[4-(trifluoromethyl)benzyl]urea, *N*-Isoquinolin-5-yl-*N*-[3-(trifluoromethyl)benzyl]urea, *N*-Isoquinolin-5-yl-*N*-[2-[4-(trifluoromethyl)phenyl]ethyl]urea, *N*-(2-Oxidoisoquinolin-5-yl)-*N*-[4-(trifluoromethyl)benzyl]urea, *N*-Isoquinolin-5-yl-*N*-[2-[3-(trifluoromethyl)phenyl]ethyl]urea, *N*-Isoquinolin-5-yl-*N*-[3-[4-(trifluoromethyl)phenyl]propyl]urea, *N*-Isoquinolin-8-yl-*N*-[4-(trifluoromethyl)benzyl]urea, *N*-[3-Fluoro-4-(trifluoromethyl)benzyl]-*N*-isoquinolin-5-ylurea, *N*-[2-Fluoro-4-(trifluoromethyl)benzyl]-*N*-isoquinolin-5-ylurea, *N*-Isoquinolin-5-yl-*N*-[3-[3-(trifluoromethyl)phenyl]propyl]urea, *N*-Isoquinolin-5-yl-*N*-[4-(trifluoromethoxy)benzyl]urea, *N*-[6-(4-Fluorophenyl)pyridin-3-yl]methyl)-*N*-isoquinolin-5-ylurea, *N*-Isoquinolin-8-yl-*N*-[3-[4-(trifluoromethyl)phenyl]propyl]urea, *N*-Quinolin-5-yl-*N*-[3-[4-(trifluoromethyl)phenyl]propyl]urea, *N*-Isoquinolin-8-yl-*N*-[3-[3-(trifluoromethyl)phenyl]propyl]urea, *N*-Quinolin-5-yl-*N*-[3-[3-(trifluoromethyl)phenyl]propyl]urea, *N*-Isoquinolin-8-yl-*N*-[4-(trifluoromethoxy)benzyl]urea, *N*-

Attorney Docket No.: T1566P  
 Application No.: 10/505,538  
 Filing Date: August 19, 2004  
 Page No.: 6

Quinolin-5-yl-*N'*-[4-(trifluoromethoxy)benzyl]urea, *N*-(2,3-Dihydro-1*H*-inden-2-ylmethyl)-*N'*-isoquinolin-5-ylurea, *N*-Isoquinolin-5-yl-*N'*-(4-phenylcyclohexyl)urea, *N*-Isoquinolin-5-yl-*N'*-(6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulen-6-ylmethyl)urea, *N*-Isoquinolin-5-yl-*N'*-(6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulen-7-ylmethyl)urea, *N*-isoquinolin-5-yl-*N'*-{[5-(trifluoromethyl)pyridin-2-yl]methyl}urea, *N*-[(4-*tert*-Butylpyridin-2-yl)methyl]-*N'*-isoquinolin-5-ylurea, *N*-[(6-*tert*-Butylpyridin-3-yl)methyl]-*N'*-isoquinolin-5-ylurea, *N*-[(2-*tert*-Butylpyridin-4-yl)methyl]-*N'*-isoquinolin-5-ylurea, *N*-[(6-*tert*-Butylpyridin-2-yl)methyl]-*N'*-isoquinolin-5-ylurea, *N*-Isoquinolin-5-yl-*N'*-{[6-(trifluoromethyl)pyridin-3-yl]methyl}urea, *N*-Isoquinolin-5-yl-*N'*-{[3-[6-(trifluoromethyl)pyridin-3-yl]propyl]urea, *N*-Isoquinolin-5-yl-*N'*-[3-(1*H*-pyrazol-1-yl)benzyl]urea, *N*-Isoquinolin-5-yl-*N'*-[4-(1*H*-pyrazol-1-yl)benzyl]urea, *N*-Isoquinolin-5-yl-*N'*-[(2-phenyl-1,3-thiazol-5-yl)methyl]urea, *N*-Isoquinolin-5-yl-*N'*-[(2-thien-2-yl-1,3-thiazol-4-yl)methyl]urea, *N*-Isoquinolin-5-yl-*N'*-[(4-phenyl-1,3-thiazol-2-yl)methyl]urea, *N*-Isoquinolin-5-yl-*N'*-[(2-phenyl-1,3-thiazol-4-yl)methyl]urea, *N*-Isoquinolin-5-yl-*N'*-[2-(4-phenyl-1,3-thiazol-2-yl)ethyl]urea, *N*-Isoquinolin-5-yl-*N'*-[(5-phenylisoxazol-3-yl)methyl]urea, *N*-Isoquinolin-5-yl-*N'*-[(3-phenylisoxazol-5-yl)methyl]urea, *N*-(8-Fluoroisoquinolin-5-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea, *N*-Isoquinolin-5-yl-*N'*-methyl-*N'*-[4-(trifluoromethyl)benzyl]urea, *N'*-Isoquinolin-5-yl-*N*-methyl-*N*-[4-(trifluoromethyl)benzyl]urea, *N*-Isoquinolin-5-yl-*N'*-{[1-[4-(trifluoromethyl)phenyl]ethyl]urea, *N*-(1,3-Diphenylpropyl)-*N'*-isoquinolin-5-ylurea, *N*-Isoquinolin-5-yl-*N'*-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]urea, *N*-[(2-Benzyl-1,3-thiazol-4-yl)methyl]-*N'*-isoquinolin-5-ylurea, *N*-Isoquinolin-5-yl-*N'*-{[1-(2-methylphenyl)-1*H*-pyrazol-4-yl]methyl}urea, *N*-(3-Methoxyisoquinolin-8-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea, *N*-Cinnolin-5-yl-*N'*-[4-(trifluoromethyl)benzyl]urea, *N*-(4-*tert*-Butylbenzyl)-*N'*-cinnolin-5-ylurea, *N*-(3-Cyclohexylpropyl)-*N'*-isoquinolin-5-ylurea, *N*-Isoquinolin-5-yl-*N'*-(6,7,8,9-tetrahydro-5*H*-benzo[*a*][7]annulen-7-yl)urea, *N*-Isoquinolin-5-yl-*N'*-[4-(trifluoromethyl)benzyl]thiourea, *N*-Isoquinolin-6-yl-*N'*-[4-(trifluoromethyl)benzyl]urea, *N*-Isoquinolin-6-yl-*N'*-[4-(trifluoromethoxy)benzyl]urea, *N*-(3-Methylisoquinolin-5-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea, *N*-(1-Chloroisoquinolin-5-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea, *N*-[1-(Dimethylamino)isoquinolin-5-yl]-*N'*-[4-(trifluoromethyl)benzyl]urea, *N*-(3-Methylisoquinolin-5-yl)-*N'*-[4-(trifluoromethoxy)benzyl]urea, *N*-(3-Methylisoquinolin-8-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea, *N*-(3-Chloroisoquinolin-5-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea, *N*-(3-Methylcinnolin-5-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea, *N*-Cinnolin-5-yl-*N'*-[4-(trifluoromethoxy)benzyl]urea, *N*-(1-hydroxyisoquinolin-5-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea, *N*-[4-(trifluoromethyl)benzyl]-*N'*-[3-(trifluoromethyl)isoquinolin-5-yl]urea, *N*-(1-chloro-3-ethylisoquinolin-5-yl)-*N'*-[4-(trifluoromethyl)benzyl]urea, *N*-phenyl-*N'*-[quinolin-6-yl]urea, *N*-(2-naphthyl)-*N'*-[quinolin-6-yl]urea, *N*-(4-nitrophenyl)-*N'*-[quinolin-6-yl]urea, *N*-[3,5-bis(trifluoromethyl)phenyl]-*N'*-[quinolin-6-yl]urea, *N*-(4-phenoxyphenyl)-*N'*-[quinolin-6-yl]urea, *N*-(4-

Attorney Docket No.: T1566P  
Application No.: 10/505,538  
Filing Date: August 19, 2004  
Page No.: 7

acetylphenyl)-N'-[quinolin-6-yl]urea, N-benzyl-N'-[quinolin-6-yl]urea, N-[quinolin-6-yl]-N'-[4-(trifluoromethoxy)phenyl]urea, N-(4-cyanophenyl)-N'-[quinolin-6-yl]urea, N-(1,1'-biphenyl-4-yl)-N'-[quinolin-6-yl]urea, N-[4-(dimethylamino)phenyl]-N'-[quinolin-6-yl]urea, N-(1,3-benzodioxol-5-yl)-N'-[quinolin-6-yl]urea, N-cyclohexyl-N'-[quinolin-6-yl]urea, N-[(+/-)-1-phenylethyl]-N'-[quinolin-6-yl]urea, N-(1-Methylisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-(1-Methylisoquinolin-5-yl)-N'-[4-(trifluoromethoxy)benzyl]urea, N-(6,8-Difluoro-3-methylisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-[3-Methyl-7-(trifluoromethyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea, N-(8-Fluoro-3-methylisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-(6-Fluoro-3-methylisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-(6-Fluoro-3-methylisoquinolin-5-yl)-N'-[4-(trifluoromethoxy)benzyl]urea, N-(3-Methylcinnolin-5-yl)-N'-[4-(trifluoromethoxy)benzyl]urea, N-(7-Methoxyisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-(1,3-Dimethylisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-(7-Chloro-3-methylisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-(7-Chloroisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-(8-Fluoro-3-methoxyisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-(6-Fluoroisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-(6-Fluoroisoquinolin-5-yl)-N'-[4-(trifluoromethoxy)benzyl]urea, N-(7-Fluoroisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-(4-Methylisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-[8-(trifluoromethyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea, N-[6-(trifluoromethyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea, N-[7-(trifluoromethyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea, N-[7-(trifluoromethyl)isoquinolin-5-yl]-N'-[4-(trifluoromethoxy)benzyl]urea, N-(6-Fluoro-1-methylisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-(1-Cyanoisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-[1-(Methoxycarbonyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea, N-(1-Carboxyisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-(1-Aminoisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-[1-(Hydroxymethyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea, N-[3-(Methoxycarbonyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea, N-(3-Carboxyisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-[3-(Dimethylamino)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea, N-[3-(2-Aminoethyl)isoquinolin-5-yl]-N'-[4-(trifluoromethyl)benzyl]urea, N-(8-Methoxyisoquinolin-5-yl)-N'-[4-(trifluoromethyl)benzyl]urea, N-Isoquinolin-7-yl-N'-[4-(trifluoromethyl)benzyl]urea, N-N'-Diisoquinolin-5-ylurea, N-Isoquinolin-5-yl-N'-[4-(trifluoromethyl)phenyl]urea, N-Isoquinolin-5-yl-N'-[2-(trifluoromethyl)pyrimidin-5-yl]methylurea, Ethyl 3-[[[(isoquinolin-5-ylamino)carbonyl]amino]-2-[4-(trifluoromethyl)benzyl]propanoate, 3-[[[(isoquinolin-5-ylamino)carbonyl]amino]-2-[4-(trifluoromethyl)benzyl]propanoic acid, N-Isoquinolin-5-

Attorney Docket No.: T1566P  
Application No.: 10/505,538  
Filing Date: August 19, 2004  
Page No.: 8

yl-*N'*-[4-(morpholin-4-ylmethyl)benzyl]urea, and *N*-Isoquinolin-5-yl-*N'*-[2-(2-morpholin-4-ylethoxy)-4-(trifluoromethyl)benzyl]urea.